OBJECTIVE: To define the current treatment practice of Guillain-Barré syndrome (GBS). METHODS: The study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account. RESULTS: We excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE. CONCLUSIONS: In current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations.
Current treatment practice of Guillain-Barré syndrome / C. Verboon, A.Y. Doets, G. Galassi, A. Davidson, W. Waheed, Y. Pereon, N. Shahrizaila, S. Kusunoki, H.C. Lehmann, T. Harbo, S. Monges, P. Van den Bergh, H.J. Willison, D.R. Cornblath, H.R. Jacobs B. C., K. Gorson, H. Hartung, P. Van Doorn, B. Van den Berg, J. Roodbol, M. Van Woerkom, R. Reisin, S. Reddel, Z. Islam, B. Islam, Q. Mohammad, T. Feasby, E. Dardiotis, E. Nobile-Orazio, K. Bateman, I. Illa, L. Querol, S. Hsieh, G. Chavada, J. Addington, S. Ajroud-Driss, H. Andersen, G. Antonini, A. Ariatti, S. Attarian, U. Badrising, F. Barroso, L. Benedetti, A. Beronio, M. Bianco, D. Binda, C. Briani, C. Bunschoten, J. Bürmann, I. Bella, T. Bertorini, R. Bhavaraju-Sanka, T. Brannagan, M. Busby, S. Butterworth, C. Casasnovas, G. Cavaletti, C. Chao, S. Chen, S. Chetty, K. Claeys, M. Conti, J. Cosgrove, M. Dalakas, C. Demichelis, M. Derejko, U. Dillmann, M. Dimachkie, K. Doppler, C. Dornonville de la Cour, A. Echaniz-Laguna, F. Eftimov, C. Faber, R. Fazio, C. Fokke, T. Fujioka, E. Fulgenzi, T. Garcia-Sobrino, M. Garssen, H. Georgios, C. Gijsbers, J. Gilchrist, J. Gilhuis, E. Giorli, J. Goldstein, N. Goyal, V. Granit, A. Grapperon, G. Gutiérrez, R. Hadden, J. Holbech, J. Holt, C. Pedret, M. Htut, K. Jellema, I. Pascual, M. Jimeno-Montero, K. Kaida, S. Karafiath, H. Katzberg, L. Kiers, B. Kieseier, K. Kimpinski, R. Kleyweg, N. Kokubun, N. Kolb, K. Kuitwaard, S. Kuwabara, J. Kwan, S. Ladha, L. Lassen, V. Lawson, D. Ledingham, S. Lucy, M. Lunn, A. Magot, H. Manji, C. Marchesoni, G. Marfia, C. Infante, E. Hernandez, G. Mataluni, M. Mattiazi, C. Mcdermott, G. Meekins, J. Miller, G. Morís de la Tassa, J. Physiotherapist, C. Nascimbene, R. Nowak, P. Balaguer, M. Osei-Bonsu, E. Pan, A. Pardal, J. Pardo, M. Pasnoor, M. Pulley, Y. Rajabally, S. Rinaldi, C. Ritter, R. Roberts, I. Rojas-Marcos, S. Rudnicki, M. Ruiz, G. Sachs, J. Samijn, L. Santoro, A. Savransky, A. Schenone, L. Schwindling, M. Tous, Y. Sekiguchi, K. Sheikh, N. Silvestri, S. Sindrup, C. Sommer, B. Stein, A. Stino, A. Spyropoulos, J. Srinivasan, R. Styliani, H. Suzuki, H. Tankisi, D. Tigner, P. Twydell, P. Van Damme, A. Van der Kooi, G. Van Dijk, T. Van der Ree, R. Van Koningsveld, F. Valzania, J. Varrato, F. Vermeij, J. Verschuuren, L. Visser, M. Vytopil, M. Wilken, C. Wilkerson, P. Wirtz, Y. Yamagishi, L. Zhou, S. Zivkovic. - In: NEUROLOGY. - ISSN 0028-3878. - 93:1(2019 Jul), pp. e59-e76. [10.1212/WNL.0000000000007719]
Current treatment practice of Guillain-Barré syndrome
E. Nobile-OrazioMembro del Collaboration Group
;C. Nascimbene;
2019
Abstract
OBJECTIVE: To define the current treatment practice of Guillain-Barré syndrome (GBS). METHODS: The study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account. RESULTS: We excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE. CONCLUSIONS: In current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations.File | Dimensione | Formato | |
---|---|---|---|
e59.full.pdf
accesso riservato
Dimensione
740.75 kB
Formato
Adobe PDF
|
740.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.